Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Open accessThe DOI matches its Crossref record; 144 of the 145 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases represent nowadays one of the major health problems. Despite the efforts made to unveil the mechanism leading to neurodegeneration, it is still not entirely clear what triggers this phenomenon and what allows its progression. Nevertheless, it is accepted that neurodegeneration is a consequence of several detrimental processes, such as protein aggregation, oxidative stress, and neuroinflammation, finally resulting in the loss of neuronal functions. Starting from these evidences, there has been a wide search for novel agents able to address more than a single event at the same time, the so‐called multitarget‐directed ligands (MTDLs). These compounds originated from the combination of different pharmacophoric elements which endowed them with the ability to interfere with different enzymatic and/or receptor systems, or to exert neuroprotective effects by modulating proteins and metal homeostasis. MTDLs have been the focus of the latest strategies to discover a new treatment for Alzheimer’s disease (AD), which is considered the most common form of dementia characterized by neurodegeneration and cognitive dysfunctions. This review is aimed at collecting the latest and most interesting target combinations for the treatment of AD, with a detailed discussion on new agents with favorable in vitro properties and on optimized structures that have already been assessed in vivo in animal models of dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Given the multifactorial nature of AD523”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [523]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125 · cited 1×
“Amongst the latter, the Fatty Acid Amide Hydrolase (FAAH) was originally identified as the enzyme responsible for AEA hydrolysis [96] while the Monoacylglycerol Lipase (MGL) plays a pivotal role in the regulation of 2-AG levels [97].”
BackgroundBrown, R. H., & Al-Chalabi, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1603471 · Cited by 2,125
Erasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989 · cited 1×
“that catalyzes the removal of acetyl groups from the lysine residues of both histone and nonhistone proteins [116].”
BackgroundTherapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768 · cited 1×
“It is involved in several cellular processes and signaling pathways and its dysregulation occurs in the development of different disorders [35].”
BackgroundHDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644 · cited 1×
“In particular, HDAC2 and HDAC3 have a critical role in controlling memory-related genes [120], while dampening HDAC6 activity enhances pTAU and Aβ clearance [121– 122].”
BackgroundAlzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551 · cited 1×
“ACh plays a pivotal role in cognitive processes, and disruptions in its neurotransmission can influence all the aspects of cognition and behavior, not only in AD but also in other age-related forms of dementia [27].”
BackgroundHistone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Role of Glutamate and NMDA Receptors in Alzheimer’s Disease
Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009 · cited 1×
“Recently, the activation of NMDARs has been linked to AD-related synaptic dysfunctions [64] and the NMDAR noncompetitive antagonist Memantine has been approved as symptomatologic treatment for moderate to severe AD [65].”
Background
Cited by
Items 101–132 of 132
Khedraoui, M., Karim, E. M., Yamari, I., Errougui, A., Dermawan, D., Alotaiq, N., & Chtita, S. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48040407 · Cited by 1
Bindra, S., Jeong, W. K., Kabier, M., Kumar, S., Sudevan, S. T., Vishwakarma, H. C., Parambi, D. G. T., Maliyakkal, N., Kumar, U., Pappachen, L. K., et al. (2026) · Chemistry & Biodiversity · doi:10.1002/cbdv.71405 · Cited by 1
Mittal, D., Solanki, P., Jain, G. K., Jhawat, V., Kesharwani, P., Dutt, R., Arora, S., & Singh, R. P. (2026) · 3 Biotech · doi:10.1007/s13205-026-05048-8 · Cited by 1
“Levodopa (L-DOPA) remains the gold standard, replenishing dopamine in the striatum; however, its long-term use leads to motor fluctuations and dyskinesia due to erratic plasma levels and progressive neuronal loss (Maramai et al. 2020).”
Structural Scaffolds as Anti- Alzheimer Agents
Alka, T., Sati, B., & Chaudhary, A. (2022) · Medicinal Chemistry · doi:10.2174/1573406418666220815101124 · Cited by 2
Álvarez-Córdoba, M., Reche-López, D., Cilleros-Holgado, P., Talaverón-Rey, M., Villalón-García, I., Povea-Cabello, S., Suarez-Rivero, J. M., Suárez-Carrillo, A., Munuera-Cabeza, M., Piñero-Pérez, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1629815/v1
Álvarez-Córdoba, M., Reche-López, D., Cilleros-Holgado, P., Talaverón-Rey, M., Villalón-García, I., Povea-Cabello, S., Suarez-Rivero, J. M., Suárez-Carrillo, A., Munuera-Cabeza, M., Piñero-Pérez, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1629815/v2
Álvarez-Córdoba, M., Reche-López, D., Cilleros-Holgado, P., Talaverón-Rey, M., Villalón-García, I., Povea-Cabello, S., Suarez-Rivero, J. M., Suárez-Carrillo, A., Munuera-Cabeza, M., Piñero-Pérez, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1629815/v3
Álvarez-Córdoba, M., Reche-López, D., Cilleros-Holgado, P., Talaverón-Rey, M., Villalón-García, I., Povea-Cabello, S., Suarez-Rivero, J. M., Suárez-Carrillo, A., Munuera-Cabeza, M., Piñero-Pérez, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1629815/v4
Polypharmacology in Clinical Applications: Neurological Polypharmacology
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_6
Radwan, A. A., Alanazi, F. K., & Rahman, A. M. A. (2024) · Preprints.org · doi:10.20944/preprints202402.0731.v1
Ooi, L., Tang, K. S., Tan, J. B. L., & Yeong, K. Y. (2024) · ChemistrySelect · doi:10.1002/slct.202400695
Badesso, S. (2024) · Depósito Académico Digital Universidad de Navarra (University of Navarra) · doi:10.15581/10171/70194
Future Directions and Challenges in Enzyme Research for Neurodegenerative Diseases
Rathi, K. M., Pingat, P., & Firdous, S. M. (2024) · Springer eBooks · doi:10.1007/978-981-97-6822-6_10 · Cited by 1
Wang, Y., Dai, X., Zhu, X., Wang, W., Wang, C., Li, S., Sun, S., Gao, X., & Qin, K. (2025) · Biomedical Chromatography · doi:10.1002/bmc.70076
Askarani, H. K., Iraji, A., Rastegari, A., Abbas Bukhari, S. N., Firuzi, O., Akbarzadeh, T., & Saeedi, M. (2020) · Figshare · doi:10.6084/m9.figshare.13152309
Álvarez-Córdoba, M., Reche-López, D., Cilleros-Holgado, P., Talaverón-Rey, M., Villalón-García, I., Povea-Cabello, S., Suárez-Rivero, J. M., Suárez-Carrillo, A., Munuera-Cabeza, M., Piñero-Pérez, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20462160
Tyrosine Kinase as the Therapeutic Target for Neurodegenerative Diseases
Mandal, N., Bej, A., Das, A., & Nandi, A. (2025) · IGI Global eBooks · doi:10.4018/979-8-3373-4627-4.ch010
Martínez-Orozco, H., Andrade-Guerrero, J., Pasten-Castrejón, N. J., Rodríguez‐Tanty, C., & Díaz-Cintra, S. Y. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71589 · Cited by 1
Gupta, S., Adhikary, T., Das, P., & Basak, P. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100452
Gene–Environment Interactions in Metal-Associated Neurodegenerative Diseases
Elavarasi, T., Saranraj, P., & Lokeshwari, B. (2026) · IGI Global eBooks · doi:10.4018/979-8-2600-1403-5.ch005
Neuro Rescue from Nature: Evidence-Based Herbal Strategies for Brain Health
Surendra, G. (2026) · Journal of chemical health risks
Rakshana, V., & Srinivasan, R. (2026) · Advances in Pharmacology and Pharmacy · doi:10.13189/app.2026.140408
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“These therapies target many pathways, either enhancing their effects or collaborating to get superior outcomes (237).”
BindingDB Entry 50022809: Chromenone: An emerging scaffold in anti-Alzheimer drug discovery.
BindingDB (2026) · UC San Diego · doi:10.7270/q26m3cnw
BindingDB (2023) · UC San Diego · doi:10.7270/q25t3qmb
Almalki, A. J., Ibrahim, T. S., AlAwadh, M. A., Alkhilaiwi, F., & Alharbi, A. S. (2026) · Polycyclic aromatic compounds · doi:10.1080/10406638.2026.2752853
Tokárová, Z., & Tokár, K. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.129112
Metadata
- Authors
- Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S.
- Affiliations
- University of Siena (IT)
- Conservatoire National des Arts et Métiers (FR)
- Stanford Medicine (US)
- Helmholtz Institute for Pharmaceutical Research Saarland (DE)
- Corresponding author
- Maramai, Samuele
- Yahiaoui, Samir
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2020-01
- Volume
- 2020
- Issue
- 1
- Pages
- 5120230-5120230
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- PMC
- PMC7354643
- OpenAlex
- W3039786831
- Cited by
- 121
- References
- 145
- Citations by year
- 2026: 14 · 2025: 17 · 2024: 20 · 2023: 17 · 2022: 29 · 2021: 22 · 2020: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BioMed Research International (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- HZI (Helmholtz Centre for Infection Research) (submittedVersion, cc-by-nc-sa)
- Use Siena air (University of Siena) (submittedVersion, cc-by)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, multi-target-directed ligands, multi-target therapy, neurodegeneration, protein aggregation, oxidative stress, neuroinflammation, neuroprotection, metal homeostasis, drug discovery, animal models of dementia
- MeSH terms
- Alzheimer Disease, Animals, Humans, Ligands, Oxidative Stress, Neuroprotective Agents, Molecular Targeted Therapy, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.